DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 573

[DOCKET NO. 94F-0283]

Food Additives Permitted in the Feed and Drinking Water of Animals; Menadione Nicotinamide Bisulfite

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; republication and opportunity to file objections or additional information.

SUMMARY: The Food and Drug Administration (FDA) is republishing, with additional information, a final rule that published in the Federal Register of January 2, 1996 (61 FR 5). The rule amended the food additive regulations (animal use) to reflect approval of a food additive petition (FAP) filed by Vanetta (U.S.A.) Inc. Objections to the final rule were filed. FDA is not acting on the objections in this document, but is clarifying the basis of approval of the petition and providing additional information. The agency also is providing a new 30-day period for the submission of objections or additional information in support of the objections that were previously filed. FDA has not stayed the effective date of the final rule, effective January 2, 1996.

DATES: Objections, additional information in support of the previously filed objections, or additional written objections and requests for a hearing, must be submitted by September 27, 1999.

ADDRESSES: Submit written objections and/or additional information in support of objections previously submitted to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Sharon A. Benz, Center for Veterinary Medicine's (CVM's) guidance document entitled “Guideline on the Conduct of Clinical Investigations: Responsibility of Clinical Investigators and Monitors for Investigational New Animal Drug Studies,” October 1992 (the guidelines cited by the objection were supplanted by a revised document in May 1997) (Ref. 2).

3. Heterochemical objects to the regulation in that it establishes MNB as a source of supplemental niacin and authorizes labeling the product as a source of supplemental niacin. Based on a low level of niacin supplementation, the firm contends that the labeling promotes deception of the consumer and results in misbranding of food within the meaning of the Federal Food, Drug, and Cosmetic Act (the act). The preamble of the January 2, 1996, final rule stated that FDA evaluated the data presented in the petition and concluded that use of the product is safe. The final rule stated that the food additive regulation could be amended as requested by Vanetta. FDA is now republishing the final rule to clarify its basis for approval, and to provide additional information supporting approval of the petitioned use, specifically the GLP statement as described in § 571.1(k). FDA believes this course of action is appropriate to supplement the record. FDA will also clarify the reasons for approving the FAP, and provide Heterochemical and any other interested party with an opportunity to proffer facts that demonstrate FDA’s basis for approving FAP 2228 was incorrect.

FDA is therefore republishing the final rule and providing an additional 30 days for submission of objections or additional information in support of the objections that have already been filed. In accordance with its discretion under section 409(f) of the act (21 U.S.C. 348(f)), FDA is not staying the final rule. FDA will consider a stay, however, if one is requested, after having evaluated any objections or other information filed in response to this document.

II. Administrative Record

A. Question of Adherence to GLP’s (Part 58 and § 571.1(k))

In filing an FAP, the petitioner is required to provide data and information to support the safe use of the product as required by section 409(c)(1) of the act. The supporting data and information include full reports of investigations made with respect to the safety of use of the additive, including information as to the methods and controls used in conducting the investigations. Part 58 prescribes GLP’s for conducting those nonclinical laboratory studies that are used to support or are intended for use to support FAP’s or marketing permits for products regulated by FDA. Compliance with GLP’s is intended to ensure the quality and integrity of the safety data filed to support approval of an FAP. If nonclinical laboratory studies are involved, an FAP shall include, for each study, a statement that the study was conducted in compliance with GLP requirements set forth under part 58, or if the study was not conducted in compliance with the GLP’s, a brief statement with the reason for noncompliance.

In FAP 2228, Vanetta submitted a journal article (Ref. 1) supporting approval of its petition. The studies reported in the article were not conducted in accordance with GLP’s, and Vanetta did not submit a statement of the reason for noncompliance. Accordingly, FDA is reopening the administrative record to include a statement from Vanetta on the reasons for the studies’ noncompliance with GLP’s, as required under § 571.1(k).
B. Clarification of the Record

The objections Heterochemical filed in response to FDA's approval of MNB point out that the basis for the agency's decision was not clear. The administrative record for FAP 2228 included various agency comments on the studies reported in the journal article by Oduho et al. The objector interpreted the comments to mean that the studies were invalid and thus did not support approval of the FAP. Contrary to the objector's interpretation, the agency's comments on the Oduho studies did not question their validity, and do not invalidate the agency's final decision that MNB is safe and achieves its intended technical effect. However, the objections made it clear that the agency needed to make additional comments to clarify the record.

1. Target Animal Safety

FAP 2228 included the Oduho article to support safety of MNB. The Oduho article included what was described as a chronic study (Ref. 1). The results reported in the article indicated that MNB is a safe and effective source of vitamin K and niacin activities. Niacin can serve as a generic name for all pyridine-3-carboxylic acids that exhibit nicotinamide activity (Ref. 3). Only when doses exceed 1,000 times the chick's vitamin K requirement did the article's authors report morbidity or mortality. The data generated by the chronic study, where up to 6 g of menadione per kilogram (kg) complete feed were fed to chick's, support the safety of the substance.

Although this chronic study was of relatively short duration (14 days), the agency believes that it is sufficient to support its conclusion that MNB is safe. The agency evaluated the results of the study in conjunction with the following and other available information that further supported its final determination that MNB is safe and achieves its intended technical effect. MNB hydrolyzes into menadione and nicotinamide. Menadione is prior sanctioned as a source of vitamin K activity (Ref. 4), and nicotinamide (niacinamide) is generally recognized as safe as a nutrient and/or dietary supplement under 21 CFR 582.5535 and section 201(s) of the act (21 U.S.C. 321(s)). Both components have a long history of safe use in animal diets (Refs. 4 and 5).

2. Utility

Menadione and many of its derivatives have vitamin K activity. This vitamin has several biological functions, one of the most important being in blood clot formation (Ref. 6). The Oduho article included a study demonstrating that inclusion of MNB in chick diets improved blood clotting when compared to negative controls. The improvements observed in the study were similar to those seen when another accepted source of vitamin K activity was added to experimental diets.

The highest level of menadione utilized in this study, 0.4 milligram (mg)/kg diet, approaches that recommended by the National Research Council, 0.5 mg/kg, for the type of birds used in this experiment (Ref. 7). The adequacy of 0.4 mg to meet the birds' nutritional requirement is demonstrated by the fact that the prothrombin times of 17 and 19 seconds for MNB and menadione dimethyl pyrimidinol bisulfite (MPB), an accepted source of vitamin K activity (21 CFR 573.620), fall very close to the normal range for chickens, which has been reported to vary from 20 to 25 seconds (Ref. 8). The Oduho article reported the normal prothrombin range for chicks to be 12 to 25 seconds. The bioavailability of the vitamin K activity, supplied by the menadione component of MNB, did not differ significantly from that of the positive control substance, MPB. Both MNB and MPB were bioequivalent as an active source of menadione.

The agency noted that the levels of nicotinamide utilized in Oduho experiment number 2 are below those accepted as nutritionally adequate. However, this study did demonstrate that the nicotinamide portion of the MNB molecule was available to the chicks, i.e., that it is bioavailable to a similar extent as pure nicotinamide, which served as a control in the study. In addition, the low level of nicotinamide supplementation is closer to the level of this vitamin supplied by MNB with the mandated 2 g per ton complete feed restriction. Both the amount of nicotinamide supplied by MNB and other dietary sources of this compound will be utilized to formulate a diet which meets the animal's niacin nutritional requirements.

Vanetta amended its petition and submitted a preliminary report on clinical studies conducted at the University of Georgia. This report supported the utility of MNB as a source of vitamin K activity. Because the bioavailabilities of both the menadione and nicotinamide components of MNB were established by the Oduho article, and the utility of MNB as a source of vitamin K activity was confirmed in the University of Georgia experiments, the utility portion of the amended petition was acceptable.

3. Conditions of Use and Directions for Use

The approved conditions of use, as specified in the MNB regulation (21 CFR 573.625(b)), state that MNB can be used as a "nutritional supplement in chicken and turkey feeds for both the prevention of vitamin K deficiency and as a source of supplemental niacin.”

The conditions of use appropriately compare the levels of vitamin-K activity from menadione and nicotinamide by stating that MNB can prevent a vitamin K deficiency, but is simply a source of niacin. As noted previously, niacin can serve as a generic name for all pyridine-3-carboxylic acids that exhibit nicotinamide activity (Ref. 3). By using the different terms, the conditions of use establish that MNB provides different levels of vitamin K and niacin activities.

The directions for use on the product label specify the minimum amount of menadione and niacin in MNB, and do so in units commonly used in the feed industry (Ref. 9). Animal nutritionists routinely mix feed ingredients to obtain a complete, balanced animal diet, and the composition of the diet normally changes with an animal's weight and age (Ref. 7). Therefore, users of the product will refer to the minimum amounts specified on the MNB label and mix feed accordingly with MNB and other sources of niacin to provide all nutritional needs based on the weight and age of the animal's being fed. Finally, the agency notes that the MNB label follows the Association of American Feed Control Officials (AAFCO) format, which the agency concluded was acceptable. AAFCO, primarily composed of state regulatory officials, has developed a set of model regulations for labeling. FDA generally concurs with the AAFCO model regulations although these model regulations are not binding. Feed manufacturers routinely follow the model regulations when labeling feed and are familiar with the AAFCO requirements.

III. Opportunity for Objection

A food additive shall, with respect to any particular use or intended use of such additive, be deemed to be unsafe, unless it and its use or intended use conform to the terms of an exemption that is in effect for investigational use, or there is in effect, and it and its use or intended use are in conformity with, a regulation issued under section 409(a) of the act. With respect to any intended use of a food additive, a person may file a petition with the appropriate center within FDA proposing the issuance of a regulation prescribing the conditions under which said additive may be safely used. The petition shall, in addition to any explanatory or supporting data,
contain the name of the food additive, its chemical name and composition, a statement of the conditions of the proposed use of such additive, together with all directions, recommendations, and suggestions proposed for the use of such additive with specimens of proposed labeling. The petition shall also contain relevant data bearing on the physical or other technical effect the additive is intended to produce, the quantity of the additive required to produce the desired effect, a description of practicable methods for determining the quantity of the additive in or on food and any substance formed in or on food because of its use, and full reports of investigations made with respect to the safety of the use of the additive, including information as to the methods and controls used in conducting the investigations.

Any party who will be adversely affected by this regulation may at any time on or before September 27, 1999, file with the Dockets Management Branch (address above) written objections thereto. Each objection shall be separately numbered, and each numbered objection shall specify with particularity the provisions of the regulation to which objection is made and the grounds for the objection. Each numbered objection on which a hearing is requested shall specifically so state. Failure to request a hearing for any particular objection shall constitute a waiver of the right to a hearing on that objection. Each numbered objection for which a hearing is requested shall include a detailed description and analysis of the specific factual information intended to be presented in support of the objection in the event that a hearing is held. Failure to include such a description and analysis for any particular objection shall constitute a waiver of the right to a hearing on the objection. Three copies of all documents shall be submitted and shall be identified with the docket number found in brackets in the heading of this document. Any objections received in response to the regulation may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

IV. References
4. "Food Additive Status of Vitamin K Active Substances in Animal Food" (48 FR 16748, April 19, 1983).

List of Subjects in 21 CFR Part 573
Animal feeds, Food additives.

Therefore, under the Federal Food, Drug, and Cosmetic Act, and under authority delegated to the Commissioner of Food and Drugs, FDA is republishing in its entirety the text of the final regulation that appeared in the Federal Register of January 2, 1998. This republication of the final rule does not amend the regulation in any way.

PART 573—FOOD ADDITIVES PERMITTED IN FEED AND DRINKING WATER OF ANIMALS

1. The authority citation for 21 CFR part 573 continues to read as follows:


2. Section 573.625 is renumbered as follows:

§573.625 Menadione nicotinamide bisulfite.

The food additive may be safely used as follows:
(a) Product. The additive is 1,2,3,4-tetrahydro-2-methyl-1, 4-dioxo-2-naphthalene sulfonic acid with 3-pyridine carboxylic acid amine (CAS No. 73581–79–0). (b) Conditions of use. As a nutritional supplement in chicken and turkey feeds for both the prevention of vitamin K deficiency and as a source of supplemental niacin. (c) Limitations. Not to exceed 2 grams per ton of complete feed. To assure safe use, the label and labeling shall bear adequate directions for use.

Dated: August 11, 1999.

Stephen F. Sundlof,
Director, Center for Veterinary Medicine.

[FR Doc. 99–22314 Filed 8–26–99; 8:45 am]
BILLING CODE 4160–01–F

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

24 CFR Part 103

[Docket No. FR–4433–F–02]

RIN 2529–AA86

Fair Housing Complaint Processing; Plain Language Revision and Reorganization

AGENCY: Office of the Assistant Secretary for Fair Housing and Equal Opportunity, HUD.

ACTION: Final rule.

SUMMARY: This final rule adopts an interim rule, published in the Federal Register on April 14, 1999, that revised HUD’s regulations concerning the processing of fair housing complaints.

DATES: Effective Date: September 27, 1999.

FOR FURTHER INFORMATION CONTACT: Roy Rodriguez, Acting Director, Office of Enforcement, Office of Fair Housing and Equal Opportunity, U. S. Department of Housing and Urban Development, 451 Seventh Street, SW., Washington, DC 20410–2000; telephone (202) 708–0836 (this is not a toll–free number). Hearing or speech impaired individuals may access this number via TTY by calling the toll–free Federal Information Relay Service at (800) 877–8339.

SUPPLEMENTARY INFORMATION:

I. Background

On April 14, 1999, HUD published in the Federal Register an interim rule (64 FR 18538) that revised HUD’s fair housing complaint processing regulations. The interim rule revised these regulations in two ways. First, the sections of HUD’s regulations that addressed the filing of complaints were moved to another place in the regulations. We revised these regulations to make the procedures for filing housing discrimination complaints easier to understand.

The interim rule solicited comments from the public on these revisions and included a 60–day public comment period. The public comment period closed on June 14, 1999. We received no comments on the interim rule. This final rule adopts the interim rule without change.